Molecular Therapy Submission Guide: What to Prepare Before You Submit
A practical Molecular Therapy submission guide for authors deciding whether the manuscript is strong enough, translational enough, and field-defining enough for this ASGCT flagship journal.
Associate Professor, Clinical Medicine & Public Health
Author context
Specializes in clinical and epidemiological research publishing, with direct experience preparing manuscripts for NEJM, JAMA, BMJ, and The Lancet.
Readiness scan
Find out if this manuscript is ready to submit.
Run the Free Readiness Scan before you submit. Catch the issues editors reject on first read.
How to approach Molecular Therapy
Use the submission guide like a working checklist. The goal is to make fit, package completeness, and cover-letter framing obvious before you open the portal.
Stage | What to check |
|---|---|
1. Scope | Confirm the manuscript advances the therapy field, not only one disease story |
2. Package | Tighten the abstract, first figures, and translational claims before upload |
3. Cover letter | Submit only when the paper reads like a flagship Molecular Therapy submission |
Quick answer: This Molecular Therapy submission guide starts with the most important distinction. The journal is not simply a place for any paper involving gene or cell therapy. Official journal materials describe it as a leading venue for research in gene transfer, vector development and design, stem cell manipulation, and gene-, peptide-, protein-, oligonucleotide-, and cell-based therapeutics for genetic and acquired diseases. That means editors are usually screening for field-level therapeutic consequence, not just respectable efficacy in one model.
From our manuscript review practice
Of manuscripts we review for top gene and cell therapy targets, the most common early failure is a paper that shows promise in one disease model but does not yet feel like a Molecular Therapy paper on first read.
Molecular Therapy: Key submission facts
Requirement | Details |
|---|---|
2024 JIF | 12.0 |
Quartile | Q1 |
Publisher | Cell Press for the American Society of Gene & Cell Therapy |
Submission route | Editorial Manager |
Publishing options | Open access or subscription |
Scope center | Gene and cell therapy, vectors, therapeutic platforms, and translational molecular medicine |
Official timeline signal | 136 days submission to acceptance |
What Molecular Therapy is actually screening for
Molecular Therapy is broad across therapeutic modalities but narrow in standards.
Editors are usually asking:
- does this manuscript advance the field of gene, cell, or molecular therapy rather than only one disease story
- is the therapeutic platform, vector, or intervention logic strong enough to matter beyond a single model
- do the translational claims match the evidence package
- is this best understood as a flagship Molecular Therapy paper or as a more specialized family-journal paper
That last question matters a lot now that the field has multiple adjacent outlets.
In practice, this means a manuscript can be very good and still be owner-misaligned. The flagship journal is usually holding space for papers whose therapeutic logic or platform consequence travels beyond one disease use case.
Before you submit
Pressure-test these questions before upload:
- is the therapy or platform advance the main story, not just the disease context
- does the manuscript explain why the result matters to the broader gene and cell therapy field
- are the delivery, mechanism, safety, and translational claims proportionate to the data
- is the paper better suited to Molecular Therapy itself rather than a narrower sub-journal or disease journal
- does the abstract make the therapeutic consequence visible quickly
If the manuscript depends on readers already caring about one disease area before the therapy logic becomes interesting, the fit is often weaker than authors think.
What the official materials make explicit
The journal's live public materials make its editorial identity fairly clear.
Official signal | Why it matters |
|---|---|
The journal positions itself as a leading venue for gene transfer, vector design, stem cell manipulation, and multiple therapeutic modalities | Field-level therapy relevance matters more than a narrow application result |
Subject areas center on biotechnology and molecular medicine | The paper should feel therapeutically enabling, not only biologically descriptive |
The journal supports both open-access and subscription publication | Authors should decide their route before submission instead of improvising later |
The current public insights page reports a 136-day submission-to-acceptance timeline | This is not a venue for casual or underprepared submissions |
The editorial structure includes section editors in cell therapy and clinical gene and cell therapies | The paper will be judged by people who know the translational field well |
The practical implication is that Molecular Therapy wants manuscripts that already know what kind of therapeutic contribution they are making.
That is especially important in gene and cell therapy because the field is now mature enough that encouraging proof-of-concept alone often does not carry a flagship submission. Editors want a clearer sense of what changes for the wider therapeutic community.
That broader-community test is useful before submission too. If the most compelling explanation of the paper still begins with one disease model rather than with the therapeutic advance itself, the manuscript may belong in a different journal or may still need another round of positioning.
Common failure patterns at this journal
1. The paper is more disease-specific than therapy-specific
Some manuscripts have solid disease-model efficacy but little field-level advance in vector design, delivery, engineering, or therapeutic logic.
2. The translational promise outruns the package
We often see studies where efficacy is encouraging but safety, durability, manufacturability, mechanism, or delivery constraints remain underdeveloped.
3. The manuscript belongs in a narrower home
A study may fit better in a disease-specific journal or another Molecular Therapy family title if its contribution is real but more specialized than flagship-level.
Before submission, a gene-and-cell-therapy readiness check can tell you whether the weakness is platform relevance, translational depth, or journal level.
Readiness check
Run the scan against the requirements while they're in front of you.
See score, top issues, and journal-fit signals before you submit.
Cover letter and package checklist
Before you upload, make sure the package already answers these questions:
- what is the therapeutic advance in one sentence
- why does the paper matter beyond one disease application
- do the data support the claimed translational path
- is Molecular Therapy the right family owner, not just a prestigious masthead
- have you chosen the intended publishing route before submission
At this level, the cover letter should argue field consequence and therapeutic positioning, not only novelty.
In our pre-submission review work with manuscripts targeting Molecular Therapy
In our pre-submission review work with manuscripts targeting Molecular Therapy, three patterns show up repeatedly before external review begins.
- The study has efficacy but not enough field advance. A paper can work in one model and still not yet change how the gene and cell therapy field thinks.
- The therapeutic story is broader in aspiration than in evidence. We often see strong headline claims built on early delivery or proof-of-concept data that still need durability, safety, or mechanism support.
- The manuscript has the wrong owner journal. Many papers are not bad fits for the Molecular Therapy family. They are just not necessarily flagship Molecular Therapy papers.
A therapy-platform fit check is useful here because many avoidable misses are owner-journal errors rather than fatal scientific problems.
Molecular Therapy versus nearby alternatives
Journal | Best fit | Think twice if |
|---|---|---|
Molecular Therapy | Broad, high-consequence gene and cell therapy work with field-level relevance | The paper is mainly one disease application with limited platform advance |
Molecular Therapy - Nucleic Acids | Nucleic-acid-centered therapeutic work with more specialized modality focus | The paper is broader than a nucleic-acid lane |
Nature Biotechnology | Technology platform advances with major biotechnology consequence | The manuscript is more therapy application than platform innovation |
Strong disease journal | Disease-led efficacy papers for a focused clinical or biological audience | The real contribution changes gene or cell therapy thinking more broadly |
The right choice depends on whether the manuscript's real contribution is to a therapeutic field, a modality lane, or a disease audience.
Submit If
- the manuscript advances gene, cell, or molecular therapy beyond one narrow application
- the platform, delivery, or therapeutic logic is load-bearing
- the translational claim matches the actual evidence package
- the abstract shows field-level consequence early
- the paper looks like a flagship Molecular Therapy submission on first read
Think Twice If
- the strongest result is disease-specific efficacy with weak platform consequence
- the therapy mechanism or delivery logic is still too underdeveloped
- the translational promise depends on obvious missing evidence
- a narrower Molecular Therapy family journal or disease journal is the more honest owner
Before upload, run a gene-and-cell-therapy first-read check to see whether the paper truly belongs here.
Frequently asked questions
Molecular Therapy uses an online submission workflow through Editorial Manager. The route is straightforward, but the journal is selective about whether the paper is truly advancing gene, cell, or molecular therapeutics rather than reporting a narrower disease-specific result.
Official journal materials describe Molecular Therapy as a leading journal for gene transfer, vector development and design, stem cell manipulation, and gene-, peptide-, protein-, oligonucleotide-, and cell-based therapeutics for genetic and acquired diseases. Editors are usually screening for platform or translational consequence at that level.
No. The current official journal insights page says Molecular Therapy supports both open-access publication and a subscription route. Authors should understand the publishing option they want before submission.
Common reasons include a paper that is more disease-specific than therapy-platform relevant, a study with promising efficacy but weak therapeutic mechanism or delivery logic, and a manuscript better suited to a narrower gene-therapy family journal.
Sources
Before you upload
Choose the next useful decision step first.
Move from this article into the next decision-support step. The scan works best once the journal and submission plan are clearer.
Use the scan once the manuscript and target journal are concrete enough to evaluate.
Anthropic Privacy Partner. Zero-retention manuscript processing.
Where to go next
Same journal, next question
Supporting reads
Conversion step
Choose the next useful decision step first.
Use the scan once the manuscript and target journal are concrete enough to evaluate.